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Key questions
What is already known about this subject?
 ► Balloon aortic valvoplasty (BAV) and surgical aor-
tic valvotomy (SAV) are used with good results in 
neonates and infants, but there is ongoing debate 
on whether one method achieves better outcomes 
than the other, with clinical practices varying 
considerably.
What does this study add?
 ► The current study compares BAV and SAV in a na-
tional population of 647 neonates and infants, bring-
ing patients from various practices, spanning over 
a decade.
 ► BAV and SAV were found to have comparable sur-
vival and freedom from reintervention at 10 years. 
Unadjusted survival at 10 years was 90.6% after 
initial BAV and 84.9% after initial SAV.
 ► Unadjusted aortic valve replacement rate at 10 
years was 78% after initial BAV and 80.3% after 
initial SAV. Neonatal procedures associated cardi-
ac defects and reinterventions are associated with 
worse outcomes.
How might this impact on clinical practice?
 ► The choice between BAV and SAV is currently taken 
in an individualised manner, in a multidisciplinary 
meeting.
 ► The fact that we found similar results with both 
methods supports this practice. Nevertheless, we 
identified subgroups of patients, namely neonates 
and those with associated cardiac defects, where 
outcomes are worse.
 ► Future research should be focused on determining 
clinical and imaging criteria to aid treatment choice.
AbstrAct
Objective There are conflicting data on choosing balloon 
aortic valvoplasty (BAV) or surgical aortic valvotomy (SAV) 
in neonates and infants requiring intervention for aortic 
valve stenosis. We aim to report the outcome of both 
techniques based on results from the UK national registry.
Methods This is a retrospective study, including all 
patients under 1 year undergoing BAV/SAV between 2000 
and 2012. A modulated renewal approach was used to 
examine the effect of reinterventions on outcomes.
Results A total of 647 patients (488 BAV, 159 SAV, 292 
neonates) undergoing 888 aortic valve procedures were 
included, with a median age of 40 days. Unadjusted 
survival at 10 years was 90.6% after initial BAV and 84.9% 
after initial SAV. Unadjusted aortic valve replacement (AVR) 
rate at 10 years was 78% after initial BAV and 80.3% after 
initial SAV. Initial BAV and SAV had comparable outcomes 
at 10 years when adjusted by covariates (p>0.4). AVR 
rates were higher after BAV and SAV reinterventions 
compared with initial valvoplasty without reinterventions 
(reference BAV, HR=3 and 3.8, respectively, p<0.001). 
Neonates accounted for 29/35 of early deaths after 
the initial procedure, without significant differences 
between BAV and SAV, with all late outcomes being worse 
compared with infants (p<0.005).
Conclusions In a group of consecutive neonates and 
infants, BAV and SAV had comparable survival and 
freedom from reintervention as initial procedures and 
when performed as reinterventions. These findings support 
a treatment choice based on patient characteristics and 
centre expertise, and further research into the best patient 
profile for each choice.
IntROduCtIOn
Congenital aortic valve stenosis (AS) is 
among the more common congenital heart 
defects, accounting for 6% of all congenital 
heart disease.1 When the stenosis is severe, 
it requires intervention during the neonatal 
life or early infancy. This is undertaken either 
with a balloon aortic valvoplasty (BAV) or 
surgical aortic valvotomy (SAV). Throughout 
the last decades clinicians have switched from 
one preferred option to another, as both tech-
niques evolved.2 BAV offers the advantage of 
avoiding a sternotomy and performing the 
procedure without the need for cardiopul-
monary bypass in a child with an impaired 
ventricular function, where the surgical risk 
might be prohibitive. SAV permits for direct 
visualisation of the valve and repair of the 
valve, if possible.
Currently, most centres in the UK have 
experience with both strategies, but tend to 
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favour the one with the best institutional results. This is 
mirrored in the available international published data, 
summarised in a recent meta-analysis, with only four 
single-centre and two multicentre comparative reports, 
compared with 12 reports of a single technique, as 
presented in a recent meta-analysis.3
In a landmark study published by the Congenital Heart 
Surgeons Society in 2001, BAV and SAV were shown to 
have similar outcomes in neonates, but whether the same 
is true in present times or in infant patients is debatable.4 
The publishing of this study was followed by an increased 
interest in BAV. A decade later several single-centre series 
showed superior results with the surgical approach,5–7 
and the use of SAV has regained momentum in a true 
‘pendulum swing’.2 These variations in preferences and 
use make applying current data difficult in day-to-day 
practice. In addition, few studies, if any, include large 
enough patient groups undergoing reintervention or 
with associated cardiac defects to allow for a meaningful 
analysis of more complex management pathways.
A multicentre registry, such as the UK National Congen-
ital Heart Disease Audit (NCHDA) is well equipped to 
show the contemporary picture of aortic valve interven-
tion, by including centres with diverse practices, while 
gathering sufficient numbers to allow for adjustments 
for patient characteristics. Our study aims to: (1) report 
national early and late outcomes after initial BAV or SAV 
and aortic valve reintervention; 2) identify predictors 
for late mortality and reintervention; (3) describe the 




The National Institute for Cardiovascular Outcomes 
Research (NICOR) collects validated key data on cardiac 
procedures from all the UK units in the NCHDA (https:// 
nicor4. nicor. org. uk/). Linkage with survival registries of 
Northern Ireland and Scotland cannot be performed 
consistently, while a minority of patients are private 
patients from abroad. This resulted in 7.7% (n=50) of 
patients not having follow-up data beyond 30 days. The 
remaining patients have follow-up from the Office of 
National Statistics and/or subsequent entries in the data-
base. The need for patient-level consent to participate in 
this retrospective study with anonymised data was waived 
by the NICOR Research Board.
Patient selection and classification
All available data in the registry on 727 patients either 
an initial BAV or a SAV at under 1 year of age between 
1 April 2000 and 31 March 2012 were selected and 
anonymised. We excluded 53 patients directed towards a 
single ventricle pathway and 27 patients previous proce-
dures, resulting in a final group of 647 infants and 888 
aortic valve procedures.
Reintervention was defined as any aortic valve proce-
dure, surgical or transcatheter, following an index (first) 
BAV/SAV procedure. Reinterventions were divided into 
BAV, SAV or aortic valve replacement (AVR) subgroups. 
Early events are defined as occurring within 30 days from 
the index procedure.
statistical analysis
Frequencies are given as numbers and percentages, 
continuous values as median (IQR). Population char-
acteristics were compared using the Mann-Whitney U 
test, Kruskal Wallis test and the Fisher’s exact test. As 
most variables were not normally distributed (tested with 
the Shapiro-Wilks test), we used non-parametrical tests 
throughout. Unadjusted survival and freedom from rein-
tervention at 10 years are estimated using the Kaplan-
Meier method, considering the time from the procedure 
of interest (initial BAV/SAV or reintervention) up to the 
first event of each type (death, AVR, aortic valvoplasty or 
valvotomy) and presented as percentage and 95% CI.
Patients with an associated cardiac defect had a higher 
likelihood of being selected for a surgical approach, 
regardless of other factors. To assess this possible source 
of bias, we analysed outcomes in two subgroups: isolated 
aortic valve disease (n=454, 70%) and aortic valve disease 
with an associated defect (n=193, 30%). The latter group 
of patients were matched by age, weight-for-age z score, 
gender and associated cardiac defects using a coarsened 
exact matching algorithm (‘cem’ package for STATA) 
and analysis repeated.8
To evaluate the effect of the initial procedure and the 
effect of reinterventions on outcomes, we used a modu-
lated renewal approach when building the models, reset-
ting the time-to-event variable after each reintervention 
and creating a new entry and retaining a number of time-
varying variables: type of current procedure or reinter-
vention, age at the current procedure and weight-for-age 
z score at current procedure.9
We used multivariable survival and freedom from 
reintervention Weibull regression models in the whole 
study population, using a stepwise backwards elimination 
method, including the following variables: current proce-
dure type (categorical with five values—initial BAV/SAV, 
BAV/SAV reintervention, AVR), initial age (continuous), 
neonate at initial procedure, initial weight-for-age z score, 
current procedure age, current procedure weight-for-age 
z score, patient gender, coarctation of the aorta (CoA), 
mitral valve abnormality, ventricular septal defect, atrial 
septal defect, subaortic stenosis, right ventricular outflow 
tract obstruction, genetic syndrome. At each step, the 
variable with the higher p value was excluded, until all 
remaining ones had a p<0.05, in order to avoid spurious 
results. Additionally, we performed subgroup analyses 
of outcomes in neonates and patients with associated 
cardiac defects. Neonates and patients with associated 
defects were identified as potential bias sources, and 
as such sensitivity analysis was performed by excluding 
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Figure 1 Initial aortic valve procedure (BAV or SAV) trends 
between 2000 and 2011 in the UK. There was a steady 
increase of BAV performed, while the number of SAV 
decreased up to the middle of the last decade and rose in 
the latter half. BAV, balloon aortic valvoplasty; SAV, surgical 
aortic valvotomy.
Table 1 Patient and initial procedure characteristics
Initial procedure BAV (n=488) SAV (n=159) P value
Age, days (median, 
IQR)
45 (7.8;101) 27 (9;102) 0.48
Weight-for-age Z score 
(median IQR)
−0.7 (−1.7;0.2) −0.9 (−2;0.2) 0.61
Male gender (n,%) 358 (73.4%) 112 (70.4%) 0.47
Associated defects 113 (23.2) 80 (50.3) <0.001
  CoA 40 (8.2) 36 (22.6) <0.001
  MV abnormality 37 (7.6) 16 (10.1) 0.35
  SAS 21 (4.3) 14 (8.8) 0.04
  ASD 16 (3.3) 12 (7.6) 0.02
  VSD 12 (2.5) 26 (16.3) <0.001
  RVOTO 10 (2.1) 8 (5) 0.05
  Genetic syndromes 7 (1.4) 5 (3.1) 0.18
Concomitant 
procedures
  CoA correction 10 (2.1) 26 (16.3) <0.001
  MV repair/
replacement
0 3 (1.9) 0.01
  SAS relief 0 6 (3.8) <0.001
  ASD closure 0 3 (1.9) 0.01
  VSD closure 0 4 (2.5) 0.004
Follow-up, years 
(median, IQR)
4.6 (2.1;8.2) 2.9 (0.7;8.8) 0.06
ASD, atrial septal defect; CoA, coarctation of the aorta; MV, mitral 
valve; RVOTO, right ventricular outflow tract obstruction; SAS, 
subaortic stenosis; VSD, ventricular septal defect.
each subgroup and repeating the late outcomes analysis, 
without significant changes to results (data not shown).
Statistical analyses were done with STATA/IC 11.2 
(Stata, College Station, Texas, USA). Patient weight-
for-age z-score was calculated using the WHO macro for 
STATA (http://www. who. int/ childgrowth/ software/ 
en/).
Results
A total of 647 neonates and infants (488 BAV, 159 SAV) 
undergoing 888 aortic valve procedures were included. 
During the first half of the last decade, usage of SAV in the 
UK has decreased in this population, but in the second 
half there has been an increase in the number of children 
undergoing SAV, translating in an increasing proportion 
relative to BAV (figure 1). Additionally, figure 1 shows a 
steady increase in the number of patients treated each 
year. Table 1 shows patient and initial procedure charac-
teristics. The observed treatment pathways and time to 
reinterventions are summarised in figure 2, with a total 
of 98 reintervention BAV, 59 reintervention SAV and 84 
AVR.
Few patients (<2%) have more than two reinterventions 
during the observed follow-up. Median age at BAV rein-
tervention is 5.7 months (3.2;19.9), at reintervention SAV 
7.7 months (1.3; 19) and at AVR 15 months (3.1; 41.2). 
Significantly more SAV reinterventions are performed at 
less than 30 days from a previous AoV procedure (n=20, 
33.9% vs n=14, 14.3% for BAV and n=13, 15.5% for AVR, 
p<0.001).
Among the 84 AVR procedures recorded, there were 75 
(89.3%) Ross/Ross-Konno operations, 3 (3.6%) homo-
graft AVRs, 2 mechanical AVRs (2.4%), 1 bioprosthesis 
AVR (1.2%) and 3 unknown AVRs (3.6%).
early outcomes
No significant differences were found between initial 
or reintervention BAV and SAV choice in terms of early 
outcomes. Mortality at 30 days after the initial procedure 
was 5.9% overall: 5.7% after initial BAV, 6.5% after initial 
SAV, 3.2% after BAV reintervention and 9.4% after SAV 
reintervention (p=0.5). Early AVR risk was 1.7% overall; 
1.5% after initial BAV, 2.2% after initial SAV, 1.1% after 
BAV reintervention and 1.8% after SAV reintervention 
(p=0.9). Risk for early non-AVR valve reintervention was 
5.4% overall, 5.9% after initial BAV, 3.6% after initial 
SAV, 1.1% after BAV reintervention and 1.9% after SAV 
reintervention (p=0.13).
late survival
The unadjusted survival at 10 years was 89.3% (86.5; 
91.5%), 90.6% (87.5; 92.9%) after initial BAV and 84.9% 
(77.7; 89.9%) after initial SAV. We found no significant 
differences between the choice of BAV or SAV as initial 
procedure or reintervention, but we did find a signifi-
cantly higher mortality at 10 years after an AVR type rein-
tervention (adjusted HR=2.8, p=0.02, initial BAV as refer-
ence, figure 3A).
Freedom from aVR
The unadjusted freedom from AVR at 10 years was 
78.7% (73.3;83.2%), 78% (71.3;83.3%) after initial 
BAV and 80.3% (69.2;87.7%) after initial SAV. BAV and 
SAV performed as reintervention were associated with 
increased risk for subsequent AVR (adjusted HR=1.8, 
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Figure 2 Summary of the aortic valve procedures 
performed in the initial BAV group (A) and the initial SAV 
group (B), by order of reinterventions (first on the left, second 
below and middle and third to the right). Numerical values 
represent time from the previous procedure in days (median 
if >3 similar reinterventions, each separate value if three or 
less). Colour coding follows each index procedure (blue for 
initial BAV, red for initial SAV, green for reintervention BAV, 
orange for reintervention SAV and light purple for AVR). 
*There is one patient with a fourth reintervention, an AVR at 
202 days following a BAV. AVR, aortic valve replacement; 
BAV, balloon aortic valvoplasty; SAV, surgical aortic 
valvotomy.
p=0.05 and HR=2.6, p=0.003 respectively, initial BAV as 
reference, figure 3B). There was a 44.4% higher risk 
of AVR after repeat SAV compared with BAV, but this 
was not statistically significant. The subgroup sensitivity 
analysis showed that this effect was confounded by the 
subgroup with associated cardiac defects. After under-
going a reintervention AVR, the probability of a second 
AVR was significantly lower (HR 0.3, p=0.04).
Freedom from BaV/saV reinterventions
The unadjusted freedom from BAV reintervention at 10 
years was 82.2% (76.5;86.7%) after initial BAV, 73.8% 
(62.3;82.2%) after initial SAV and 80.2% (75.2;84.3%) 
overall. Transcatheter reinterventions were significantly 
less frequent after a SAV or AVR reintervention (adjusted 
HR=0.2, p=0.04 and HR=0.05, p=0.004 respectively, initial 
BAV as reference, figure 3C).
The unadjusted freedom from SAV reintervention at 
10 years was 91% (87.3;93.6%) after initial BAV, 86.6% 
(74;93.3%) after initial SAV and 89.6% (85.3;92.7%) 
overall. Surgical reinterventions are significantly less 
frequent after an AVR (adjusted HR=0.1, p=0.03, initial 
BAV as reference, figure 3D).
Freedom from any aortic reintervention (including 
AVR) at 10 years was 61.8% (54.9;68%) after initial 
BAV, 55.2% (43.4;65.4%) after initial SAV and 60.2% 
(54.3%;65.7%) overall.
Predictors of late outcomes
Predictors of late survival and freedom from reinterven-
tion are summarised in table 2.
Outcomes in neonates
Out of the 647 patients, 292 (45%) were neonates at 
the time of the first procedure (211 in the BAV group, 
81 in the SAV group). We found higher mortality in the 
neonatal group compared with the infant group (10.3% vs 
1.9%, p<0.001), higher likelihood of AVR (3.2% vs 0.3%, 
p=0.006) and also of non-AVR reintervention (9.2% vs 
1.9%, p<0.001) at 30 days. This population accounted for 
29/35 (82%) of deaths, 9/10 (90%) of AVRs and 26/32 
(81%) of non-AVR reinterventions occurring early after 
the initial procedures, without significant differences due 
to choice between BAV and SAV. All late outcomes were 
worse in the neonatal subgroup (table 2).
Outcomes in patients with associated cardiac defects
The proportion of patients with associated cardiac 
defects was significantly higher in the SAV group when 
compared with the BAV group (50.2% vs 23.2%, p<0.001) 
as was the proportion of those undergoing concomitant 
procedures (22% vs 2%, p<0.001). The only type of 
concomitant procedures observed in the BAV group was 
treatment of CoA.
In total, there were 193 patients with associated cardiac 
defects (113 with BAV, 80 with SAV). Out of these, 45 
(23.3%) underwent concomitant procedures at the 
initial repair (10 with BAV and 35 with SAV). They had 
lower survival (86.9% vs 92.7%, p=0.04), similar freedom 
from AVR and lower freedom from any aortic valve rein-
tervention (52.3% vs 63.6%, p<0.001) at 10 years when 
compared with those with isolated aortic valve disease. In 
most cases undergoing initial SAV, there were concom-
itant repairs of other defects (35/80, 26 of which were 
CoA repair), with fewer concomitant transcatheter proce-
dures in the BAV group (10/113, all CoA dilations). SAV 
with concomitant repairs was associated with a trend 
towards increased late mortality compared with isolated 
SAV, although not statistically significant (HR 2.3, CI 0.8 
to 6.1, p=0.09).
Patients with concomitant cardiac defects in the BAV 
and SAV groups were also matched based on the age, 
weight and associated defect types. This resulted in 
54 patients with initial BAV and 26 with an initial SAV. 
An association between the choice for initial SAV and 
increased mortality was found, although not statistically 
significant, in both unmatched patients with associated 
cardiac defects (HR 2.3, CI 0.9 to 5.4, p=0.07, initial BAV 
as reference) and matched groups (HR 2.9, CI 0.9 to 9.3, 
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Figure 3 Survival and freedom from reintervention curves, adjusted by procedure type (initial/reintervention), patient 
demographic data, coexisting defects (variables shown in table 2). Data are for mean variable values, obtained from 
multivariable Weibull regression, stratified by procedure type. (A) Survival, (B) freedom from AVR, (C) freedom from BAV type 
reintervention, (D) freedom from SAV type reintervention. * denotes statistically significant difference from the baseline (blue 
line). AVR, aortic valve replacement; BAV, balloon aortic valvoplasty; SAV, surgical aortic valvotomy.
p=0.07, initial BAV as reference) and possibly confounded 
by concomitant surgical procedures. The small number 
of patients undergoing isolated initial SAV did not lend 
itself to a separate analysis.
dIsCussIOn
To our knowledge, this is the largest series of neonates and 
infants treated with either BAV or SAV and it describes 
all consecutive patients from a large multicentre national 
registry. At 10 years after the initial BAV or SAV, we 
report 89.3% survival and 78.7% freedom from AVR. We 
found no significant differences in outcomes at 10 years 
between BAV and SAV, after adjusting for covariates, 
including age and reinterventions. When BAV or SAV are 
performed as a reintervention, they are both associated 
with similarly higher rates of AVR. Neonatal intervention 
is associated with worse outcomes than in infants, without 
differences due to BAV or SAV choice. In the subgroup of 
patients with coexisting cardiac defects, we found a trend 
for higher mortality at 10 years associated with initial SAV 
and performing other concomitant cardiac procedures, 
although both comparisons were underpowered.
The number of patients with AS undergoing treatment, 
be it surgical or transcatheter has been steadily increasing, 
as evidenced by the data in figure 1. The choice between 
BAV and SAV in very young patients is a matter of 
ongoing debate and has been so for decades.2 This is 
evidenced by how the ratio between the two approaches 
has changed through the last decade in the UK, with SAV 
use gradually declining in the favour of BAV in the years 
following the landmark study by McCrindle et al in 2001.4 
Since the practice is not uniform, there were centres still 
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Table 2 Predictors of mortality and reinterventions after 
BAV and SAV procedures
HR 95% CI P value
Mortality
  Reintervention AVR 2.8 1.1 to 6.9 0.02
  Age at current procedure 
(years)
0.17/year 0.03 to 0.86 0.03
  Neonate at initial 
procedure
3 1.5 to 6.2 0.003
  Weight-for-age Z score at 
current procedure
0.78/unit 0.67 to 0.91 0.02
  SAS 0.1 0.02 to 1 0.05
  VSD 3.6 1.7 to 7.8 0.001
AVR
  Reintervention BAV* 1.9 1 to 3.4 0.04
  Reintervention SAV* 2.6 1.4 to 5.1 0.004
  Reintervention AVR* 0.3 0.1 to 0.9 0.04
  Neonate at initial 
procedure
2.1 1.3 to 3.5 0.002
  Weight-for-age Z score at 
current procedure
0.84/unit 0.74 to 0.96 0.01
  SAS 2.3 1.3 to 4.3 0.005
  Female gender 0.6 0.3 to 1 0.05
BAV
  Reintervention SAV* 0.2 0.05 to 0.9 0.04
  Reintervention AVR* 0.05 0.007 to 0.4 0.004
  Neonate at initial 
procedure
2.4 1.5 to 3.6 <0.001
  SAS 2.8 1.6 to 4.9 <0.001
SAV
  Reintervention AVR* 0.1 0.01 to 0.8 0.03
  Neonate at initial 
procedure
2.4 1.4 to 4.2 0.002
  MV defect 3.1 1.7 to 5.9 <0.001
*Reference is initial BAV.
AVR, aortic valve replacement; BAV, balloon aortic valvoplasty; 
MV, mitral valve; SAS, subaortic stenosis; SAV, surgical aortic 
valvotomy; VSD, ventricular septal defect.
opting for the surgical approach, both in the UK and 
outside, with good results, as shown by the multiple series 
promoting SAV which were published after 2010.5 6 The 
upward trend of SAV use seen in the late decade is very 
likely a result of centres looking into their own practices 
and good surgical results, as no important SAV series 
preceded these changes. Having very little high quality 
evidence led to fluid practices, influenced in equal terms 
by published work and individual centre results.
Our data on outcomes for aortic valve stenosis treat-
ment are comparable to those reported by Hill et al in a 
recent meta-analysis including 483 neonates and infants,3 
with the exception that we did not find higher reinter-
vention rates after BAV. This is likely due to the fact that 
in our study it was possible to adjust for multiple factors 
which were adding selection bias in other studies, an 
issue highlighted by the authors of the meta-analysis. In 
the first multicentre study comparing the two options in 
neonates, McCrindle and colleagues also do not report 
differences in reintervention rates.4
This report sheds light on outcomes of a large group 
of children who required aortic valve (non-AVR) rein-
tervention after an initial BAV or SAV, showing that they 
have a higher rate of later AVR during childhood, espe-
cially when they have associated cardiac defects. Crespo 
et al have previously shown a less effective peak gradient 
reduction in reintervention BAV, but do not report hard 
outcomes such as mortality or reintervention.10 Since 
balloon valvoplasty is traditionally considered to be the 
more damaging to the cusp structure out of the two 
options,11 it is reassuring that in fact when repeat proce-
dures are done, reintervention BAV and SAV appear 
comparable in terms of survival.
In the subgroup analysis on neonates, the results are 
less good. This subgroup accounted for almost half of 
total patients, but close to 90% of all early deaths or 
reinterventions observed overall. The outcomes, both 
early and late, were similar regardless of choice between 
BAV and SAV, as was found in the multicentre study by 
McCrindle et al and the meta-analysis by Hill et al.3 4
Another issue is the strategy for patients with associated 
cardiac defects. Traditionally if more than one lesion can 
be surgically addressed a larger procedure is planned 
and multiple defects are corrected. While this is based 
on sound clinical reasoning to avoid multiple operations, 
it does invite the question of how to proceed when one 
or more of the surgical steps can be performed percuta-
neously instead. To look into this issue, we studied the 
subgroup with associated cardiac defects. As expected, 
most of those undergoing SAV had multiple corrections 
performed at the index procedure (mostly CoA repair), 
while the only concomitant procedure performed in the 
BAV group was CoA dilation. Interestingly, we found 
that those with initial SAV, and among them those with 
concomitant repairs at index, had a higher late mortality, 
although not statistically significant. Even based on this 
underpowered comparison, it is reasonable to say that 
the hypothesis of better outcomes with staged, hybrid 
repair of complex cardiac defects would warrant testing 
in a prospective study, with better control of indication 
bias.
Finding no significant differences between BAV and 
SAV in terms of mortality, AVR and reintervention rates 
is encouraging, as it permits for a scenario-based deci-
sion rather than one imposed by perceived differences 
in outcomes. Our data support the consensus that both 
methods should be available as choices, as each patient 
will likely benefit more from one or the other initially and 
even both throughout their lifetime.11–13 New imaging 
techniques, especially those offering high resolution 3D 
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limitations
This study is limited by its retrospective nature and lack of 
clinical details such as echocardiographic, valve structure 
or reasoning for choosing a treatment option data. The 
large, multicentre setting and full procedural coverage 
partly reduces bias by allowing for multivariable adjust-
ment and including patients from centres favouring either 
method, but there are still confounders which cannot be 
accounted for, including centre preference. The lack 
of functional data did not permit for endpoints such as 
ventricular function, transvalvular gradient or regurgita-
tion severity to be assessed. The data request processing 
delay and administrative changes did not allow for the 
most recent 5 years to be included in the manuscript. 
Not having updated life status for 7.7% of patients might 
decrease the accuracy of statistical comparisons, but due 
to the random, administrative nature of the missing data, 
the risk of clinical bias is minimal.
COnClusIOn
In a large retrospective multicentre national registry of 
neonates and infants with critical aortic valve stenosis, 
both transcatheter valvoplasty and surgical valvotomy 
achieve comparable survival and freedom from reinter-
vention at 10 years in unselected patients. Intervention 
choice can and should be individualised for each case, 
based on operative risk, valve anatomy and future treat-
ment plans and not on perceived outcomes alone. When 
neonatal intervention or aortic valve reinterventions are 
needed, outcomes are significantly worse, a likely reflec-
tion of more dysplastic valves and precarious patient 
condition. The management strategy of patients with 
aortic valve stenosis and concomitant cardiac defects 
should be re-evaluated in prospective studies, as a staged 
approach including a transcatheter aortic valvoplasty 
appears to be associated with a lower mortality.
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